biomarkeratlas.com the Italian #NSCLC precision medicine knowledge database. #WCLC22 Umberto Malapelle OncoAlert International Society of Liquid Biopsy 4oncommunity Biomarkers Atlas

5 years update KEYNOTE-407 PhIII study presented by Silvia Novello at #ESMO22. ESMO - Eur. Oncology Biomarkers Atlas 4oncommunity Francesco Maria Lucia Reale ruas Christian Rolfo

Umberto Malapelle putting in the context the results of the PATHFINDER study presented today at the #ESMO22! Liquid biopsy for early cancer detection is moving faster than ever! International Society of Liquid Biopsy ESMO - Eur. Oncology Christian Rolfo dailyreporter.esmo.org/esmo-congress-…

Angelo Dipasquale Umberto Malapelle Alessandro Russo With the prof and king Umberto Malapelle now it's finally time to say: only the best at this #ESMO22 🤩😌👑

Sotorasib shows superior progression-free survival and an objective response rate compared to docetaxel for NSCLC. Watch Dr Silvia Novella speak to ecancer about the CodeBreaK 200 study👉 bit.ly/3DIOUtQ #ESMO22 Università di Torino

📌 #SaveTheDate "Tumore del Polmone: Al San Luigi lo #screening salvavita" 🗓 Conferenza Stampa: Torino, 11 ottobre - ore 11.30 📍Palazzo del Pozzo della Cisterna (via Maria Vittoria, 12)

Presentation in progress at #AIOM22. Something new is coming. Stay tuned! #BiomarkersAtlas #app Umberto Malapelle Novartis WALCE APS 4oncommunity OncoAlert

The great group thanks to which #ATLAS exists. #AIOM22. Thanks to all the 40 Italian centres that have joined this project!

Premio Marco Venturini #AIOM22 al grandissimo Francesco per il più bel lavoro pubblicato nel 2021 da un oncologo "under40" ! Scagliotti Giorgio #silvianovello

Seconda giornata di Congresso: Premio Marco Venturini 2022 a Francesco Passiglia. -- #AIOM22

Predictive Molecular Pathology in Lung and Gatric tumors! #AIOM22 #pathology4oncology

Quali le opportunitá, quali le sfide presenti e future per l'implementazione della biopsia liquida? 💉🏥👩‍⚕️ Dalla pratica clinica alla #3Dbiology 👓 👇🏻 youtu.be/8bnoII-kuxE #LorenaIncorvaia intervista Umberto Malapelle per Fondazione Aiom AIOM

Dr.Umberto Malapelle explains how and why the introduction of new #technologies is crucial for identifying possible mutations. #pathology4oncology OncoAlert Novartis Biomarkers Atlas Click here to watch 4oncommunity.com/approfondisci/

So great to see you in Miami, Umberto Malapelle! Published by VJ Oncology vjoncology.com/video/q_x5owrk…

Approaches for diagnosing #NSCLC are continually advancing 🫁 Join Umberto Malapelle to discuss the current recommendations for NSCLC testing and more alongside Oliver Gautschi and Isabelle Opitz! ⏰ 30th Nov at 5PM CET Register and tune in for free ⬇️

Downloaded! Biomarkers Atlas App! play.google.com/store/apps/det… Android

ATLAS: 𝗞𝗥𝗔𝗦 𝗽.𝗚𝟭𝟮𝗖 Register on Biomarkers Atlas ➡️ra.biomarkersatlas.com/search_engine/… Umberto Malapelle Francesco Pasquale Pisapia Maria Lucia Reale OncoAlert 4oncommunity

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment Dr. Amy C. Moore Francesco oncodaily.com/blog/224306 #Health #Medicine #Cancer #OncoDaily #Oncology #NSCLC #Genomics #MedX